Keryx Biopharma (KERX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Keryx Biopharma (KERX) Reports In-Line Q2 EPS
August 6, 2015 10:01 AM EDT
BTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
August 5, 2015 12:06 PM EDT
Brean Capital analyst Jonathan Aschoff lowered his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) to $22.00 (from $26.00) following Q2 results but maintained a Buy rating as the new price target still suggests 224% upside from current levels. The analyst expects more meaningful Auryxia sales to come in 2H15.
Aschoff commented, "Keryx reported 2Q15 total revenue of $2.5 million, versus consensus of $2.9 million, but we expect more... More
